Intellia Therapeutics (NTLA) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Intellia Therapeutics (NTLA) PT Lowered to $29 at Citi
May 9, 2024 4:40 PM EDTCiti analyst David Lebowitz lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $29.00 (from $31.00) while maintaining a Neutral rating.
The analyst comments "On the 1Q24 call, Intellia announced a new NTLA-2001 Ph3 trial in ATTR-PN (starting 2024). NTLA-2001s Ph3 MAGNITUDE... More
